Table 1. Genes Increasing Expression Early with V-ATPase Inhibitors and not with DFO or Low LDL.

			Fold Increase Relative to Control
Gene	Name	Function or Pathway	Baf 6 hr	Baf 12 hr	LX 12 hr	DFO 6 hr	DFO 12 h	low LDL 6 hr	low LDL 12 hr
CCNG2	cyclin G2	cell cycle control	1.5	2.0	2.0	NC	NC	NC	NC
CLCN6	chloride channel 6, isoform ClC-6a	chloride transport	8.0	2.1	NC	NC	NC	NC	NC
DUSP6	dual specificity phosphatase 6	inactivates ERK2	2.3	2.6	NC	NC	NC	NC	NC
FADSD6	delta-6 fatty acid desaturase	lipid biosynthersis	1.7	3.4	2.4	NC	NC	NC	NC
SREBF2	sterol regulatory element binding transcription factor 2	cholesterol biosynthesis	1.5	2.0	NC	NC	NC	NC	NC
TUBA1A	tubulin, alpha 1a	microtubule protein	1.3	2.1	1.4	NC	NC	NC	NC
WDR37	WD repeat domain 37	unknown	1.9	1.9	NC	NC	NC	NC	NC

Genes upregulated 2-fold or more after 12 hours in cells treated with V-ATPase inhibitors and in cells treated with 100 µM deferoxamine are listed. Baf, 15 nM bafilomycin A; LX, 200 nM LX1077; DFO, 100 µM deferoxamine; low LDL, cells incubated in medium containing LDL depleted serum.